Rationale: Vasopressin has been proposed as a potent vasoactive agent in the treatment of vasodilatory shock in adults and children. The objective of this trial was to evaluate the efficacy and safety of vasopressin as an adjunctive agent in pediatric vasodilatory shock. Methods: In this multicenter, double-blind trial, children with vasodilatory shock were randomized to receive low-dose vasopressin (0.0005-0.002 U/kg/min) or placebo in addition to open-label vasoactive agents. Vasoactive infusions were titrated to clinical endpoints of adequate perfusion. The primary outcome was time to vasoactive-free hemodynamic stability. Secondary outcomes included mortality, organ-failure-free days, length of critical care unit stay, and adverse events. Measurements and Main Results: Sixty-five of 69 children (94%) who were randomized received the study drug (33 vasopressin, 32 placebo) and were included in the analysis. There was no significant difference in the primary outcome between the vasopressin and placebo groups (49.7 vs. 47.1 hours; P 5 0.85). There were 10 deaths (30%) in the vasopressin group and five (15.6%) in the placebo group (relative risk, 1.94; 95% confidence interval, 0.75-5.05; P 5 0.24). There were no significant differences with respect to organ failure-free days (22 vs. 25.5 days; P 5 0.11), ventilator-free days (16.5 23 days; P 5 0.15), length of stay (8 vs. 8.5 days; P 5 0.93), or adverse event rate ratios (12.0%; 95% confidence interval, 22.6 to 26.7; P 5 0.15). Conclusions: Low-dose vasopressin did not demonstrate any beneficial effects in this pediatric trial. Although not statistically significant, there was a concerning trend toward increased mortality. Clinical trial registered with www.controlled-trials.com (ISRCTN11597444).
The mortality rate among pediatric patients with shock and circulatory failure remains unacceptably high, with reported rates ranging from 35 to 53% (1) (2) (3) . Aggressive volume resuscitation is the mainstay of the initial management of circulatory collapse, followed by vasoactive infusions in fluid refractory shock. The most appropriate vasoactive agent for the treatment of shock in adults and children remains controversial (4, 5) . Although exogenous catecholamines are the most commonly used agents, their effectiveness has been debated in shock states where endogenous catecholamine levels are already high, catecholamine resistance is suspected, and the emergence of unacceptable adverse effects are observed (6, 7) . Furthermore, adrenergic agents may exacerbate cellular immune dysfunction, catabolism, and unfavorable neuroendocrine responses during shock (8) . As a result, alternative drugs targeted at other pathogenic mechanisms responsible for shock and vasoplegia are of great interest.
Vasopressin is a neurohypophyseal peptide hormone with diverse actions that are mediated by tissue-specific receptors, which are classified into V 1 vascular, V 2 renal, V 3 pituitary, oxytocin, and P 2 purinergic subtypes (9) . Low-dose vasopressin and its analog terlipressin have emerged as promising therapeutic agents, particularly in vasodilatory shock states, for several reasons. First, vasopressin reverses the key pathogenic mechanisms responsible for vasoplegia and catecholamine resistance (10) . Second, at the same low doses that mediate vasoconstriction, vasopressin exhibits organ-specific vasodilator effects in the pulmonary, renal, cerebral, and coronary circulations, potentially preserving vital organ perfusion (11) . Third, endogenous vasopressin insufficiency has been demonstrated in patients with vasodilatory shock (12) ; however, impaired vaso-
AT A GLANCE COMMENTARY Scientific Knowledge on the Subject
Low-dose vasopressin has been suggested as a therapeutic agent in pediatric and adult vasodilatory shock. Although several clinical trials have been performed in adults, the efficacy and safety in pediatrics is unclear.
What This Study Adds to the Field
Contrary to previous observational studies, the results of this pediatric trial suggest that there are no clinical benefits of vasopresin for pediatric vasodilatory shock and that there is the potential for harm. The funding agencies had no role in the design and conduct of the study, in the collection, analysis, or the interpretation of the data or in the preparation, review, or approval of the manuscript.
pressin response in this setting has also been suggested, thereby raising questions as to whether hormone therapy would be beneficial (13) . Finally, vasopressin influences other key hormones central to maintaining homeostasis during shock, such as ACTH, cortisol, and prolactin (14) .
Adult trials conducted just before the start of this trial suggested a beneficial effect of vasopressin in shock (15, 16) . In contrast, the evidence for its use in pediatric patients is primarily observational (9, 17) . Children differ from adults with respect to underlying disease processes, hemodynamic responses, and oxygen utilization; accordingly, shock management strategies are not necessarily similar in children and adults (18, 19) . Based on the strong physiologic rationale for vasopressin in vasodilatory shock in pediatric critical care, we hypothesized that low-dose vasopressin would be an effective adjunct in reversing vasodilatory shock in children when compared with placebo.
METHODS

Patients and Sites
We conducted this randomized, double-blind, placebo-controlled trial in seven Canadian Pediatric Critical Care Units (PCCUs). Patients aged 1 month to 17 years with indwelling arterial and central venous catheters were eligible if they were within 24 hours of the diagnosis of vasodilatory shock, as defined by the presence of all of the following criteria: (1) volume resuscitation of at least 40 ml/kg; (2) at least 10 mg/kg/min of dopamine or any dose of epinephrine, norepinephrine, or phenylephrine; and (3) clinical evidence of vasodilatory shock (defined as a diastolic blood pressure of less than half systolic blood pressure and two of the following: tachycardia, warm extremities, or flash capillary refill). We excluded patients with the following conditions: death anticipated within 24 hours or a lack of commitment to life support, use of vasopressin or its analogs in the previous 24 hours, known history of vasospastic diathesis, concurrent use of intravenous vasodilator agents (sodium nitroprusside or phenoxybenzamine), hypersensitivity to vasopressin, severe hyponatremia (serum sodium less than 125 mM despite water restriction), known diagnosis of diabetes insipidus or syndrome of inappropriate antidiuretic hormone secretion, and pregnancy. Patients were also excluded if a low cardiac index of equal to or less than 2.5 L/min/m 2 after fluid resuscitation was measured by pulmonary artery catheter or echocardiography. The trial was approved by the Research Ethics Board at each participating institution. Written informed consent was obtained from the guardians, and assent was obtained from the patients where appropriate.
Randomization
After confirmation of eligibility, study site personnel randomly allocated participants using a central telephone-based system that was available 24 h/d. The randomization sequence was concealed and prepared by a statistician (in a 1:1 ratio), stratified according to study center using computer-generated, random-permuted blocks sizes within strata. All patients, caregivers, medical and nursing staff, investigators, and members of the Data Safety Monitoring Committee (DSMC) were masked to the study group assignment for the duration of the study.
Study Intervention
Participants were randomized to receive arginine vasopressin or normal saline placebo, prepared in identical 50-ml syringes and infused at a starting dose of 0.0005 U/kg/min. The study drug was administered in addition to the open-label vasoactive infusions that the patients were already receiving at baseline and titrated every 5 minutes up to 0.002 U/kg/min (0.05 U/min maximum total dose) to maintain a target mean arterial blood pressure (MAP) for age. Guidelines for the management of ongoing hemodynamic instability and guidelines for the use of potentially confounding cointerventions such as steroids and activated protein C were established by consensus of the Steering Committee and participating investigators. Once the patient achieved their target MAP for at least 4 hours without escalation in hemodynamic support, accompanied by clinical evidence of adequate end-organ perfusion, open-label vasoactive infusions were weaned in accordance with the recommended study guidelines. The study drug was weaned after both target MAP and end-organ perfusion were maintained without open-label infusions for at least 4 hours. The definitions and guidelines used in this trial are included in the online supplement.
Outcome Measures
Baseline characteristics such as age, weight, pediatric risk of mortality (PRISM) III (20) , multiple organ dysfunction (MODS) (21) and pediatric logistic organ dysfunction (PELOD) scores (22) , the underlying cause(s) of vasodilatory shock, plasma vasopressin, and cortisol levels were recorded. Plasma vasopressin level was measured by radioimmunoassay as previously described (23) . The primary outcome for this study was the time to vasoactive-free hemodynamic stability, defined as the time from study drug initiation to the time when all vasoactive agents were successfully discontinued. Secondary outcomes included the following: 30-day mortality, the change in organ dysfunction as determined by the PELOD and MODS scores, number of days alive and free of organ dysfunction (organ failure-free days), vasoactive infusions (vasoactive-free days), and mechanical ventilation (ventilator-free days), respectively, in the 30 days after randomization, length of PCCU stay, urine output, and MAP after study drug infusion. A modified vasoactive score was calculated to indicate the magnitude of vasoactive requirement for each participant (24) . Plasma vasopressin level was remeasured 4 hours after the study drug infusion. We also evaluated the rate of all adverse events (AEs) and serious adverse events (SAEs). An adverse event (AE) was defined as any undesirable experience occurring to a trial participant that might reasonably occur as a consequence of the study drug. An AE was considered ''serious'' if it was life threatening; prolonged patient hospitalization; was considered medically important; or resulted in persistent or significant disability, incapacity, or death. The relationship of the AEs and SAEs to the study intervention was determined by blinded assessment of the site investigator and reviewed by the DSMC.
Sample Size and Statistical Analysis
The primary outcome was time to vasoactive-free hemodynamic stability. We calculated that 69 patients were required for enrolment to achieve 90% power to detect a hazard ratio of 3 and a significance level of 5% using Lakatos' formula for survival analysis study design (25) . This sample size calculation accounted for a 34% mortality rate and a 7% possible dropout or postrandomization exclusion rate. The estimate of effect size for time to vasoactive-free hemodynamic stability and other parameters that informed the calculation were based on evidence from adult trials, current available data in children, and anecdotal experience from Canadian pediatric intensivists (1-3). We neither planned nor conducted an interim analysis. The DSMC performed periodic reviews of AEs and all SAEs as they occurred and did not recommend stopping the trial.
We report descriptive summaries of demographic and clinical characteristics of all participants at baseline. We summarized data using means (standard deviation [SD]), medians (interquartile range [IQR]), and frequencies. Primary and secondary outcomes were analyzed according to the intention-to-treat principal. We analyzed the primary outcome using a cause-specific cumulative incidence approach because death could also be considered as a competing risk (26) . Continuous secondary outcomes were analyzed using a nonparametric test (Wilcoxon Mann-Whitney). Fisher's exact tests were used for dichotomous outcomes such as use of cointervention drugs and indication for steroid use. Finally, time to discharge from PCCU after study drug administration was compared using survival analysis. Because the assumption of proportional hazard ratios was not met, a Breslow test was used to assess the difference between the two survival curves. AE and SAE rates were compared between groups using a Poisson regression model. We conducted two-sided significance testing; we considered P values of 0.05 to be significant. All analyses were performed using SPSS version 16.0 (SPSS, Inc., Chicago, IL) and R version 2.7.2.
RESULTS Patients and Treatment Assignment
A total of 512 consecutive children with shock were admitted to participating PCCUs between August 2003 and April 2007 (Figure 1 ). Of the 512 potential patients, 106 (21%) met the eligibility criteria, of whom 14 were not approached, 23 declined consent, and 69 (65% of eligible patients) were enrolled. Thirtyfive children were randomly assigned to receive vasopressin and 34 to receive placebo. Two patients in each group were withdrawn shortly after randomization but before initiation of any study procedures and without knowledge of group allocation; three of these patients no longer fulfilled eligibility criteria, and one patient was withdrawn when the attending physician chose to initiate open-label vasopressin because of rapidly progressive refractory shock. These postrandomization exclusions did not contribute to any statistical comparisons except for the baseline characteristics (27) . Three additional patients were withdrawn for SAEs, two of whom were in the placebo group. Only one of these participants was subsequently unblinded at the request of the treating physician for the purposes of initiating open-label vasopressin. There were two protocol violations: One patient in the vasopressin group temporarily received placebo for 6 hours, and the study drug was inadvertently suspended for 35 minutes in one patient in the placebo group.
The baseline characteristics were similar in the two groups ( Table 1) . The most common cause of vasodilatory shock was sepsis (78.2%). The severity of illness of the participants was similar as indicated by their PRISM III, MODS, and PELOD scores. Patients in both groups received a similar magnitude of volume resuscitation and open-label vasoactive infusions before the study intervention. Baseline vasopressin levels were inappropriately low in both groups (3.8 pg/ml), and baseline cortisol levels were markedly elevated in both groups.
Intervention and Cointerventions
The median dose of vasopressin use during the study was 0.0011 U/kg/min (interquartile range [IQR] 0.0007-0.0018) or 0.04 U/min. There were no significant differences in cointer- ventions between the two groups. A substantial proportion of patients received corticosteroids during the study period (64.6% in total; P 5 0.61), which were administered for refractory shock in the majority of cases (Table 2) .
Study Outcomes
There was no significant difference in the primary outcome between the two study groups. The median time to achieve hemodynamic stability was 49.7 hours in the vasopressin group and 47.1 hours in the placebo group (P 5 0.85). The vasoactivefree, organ failure-free and ventilator-free days, organ dysfunction scores, and the length of PCCU stay were not significantly different between the experimental and control groups. There was a significant increase in MAP 1 hour after infusion of vasopressin compared with baseline. However, there was no difference among the markers of end-organ perfusion, such as serum lactate, creatinine, and urine output, between study groups (Table 3 ). There were 10 (30%) deaths in the vasopressin group, compared with five deaths (15.6%) in the placebo group (relative risk, 1.94; 95% confidence interval [CI], 0.75-5.05; P 5 0.24). The causes of death for each patient are presented in Table 4 . The most common cause of death was refractory shock and multiple organ dysfunction. Patients presenting with septic vasodilatory shock had a mortality rate of 18.5%, compared with a mortality rate 33.3% among patients presenting with vasodilatory shock from nonseptic causes; however, the difference in mortality rate was not statistically significant in these subgroups (95% CI, 241.1 to 7.1; P 5 0.29). There was no significant association between baseline vasopressin levels and mortality (P 5 0.148). The use of steroids was similar between groups (60.6 vs. 65.6%; P 5 0.61). The concurrent use of steroids and vasopressin was not associated with a statistically significant difference in mortality, when compared with those without steroid exposure (25 vs. 7.6%; P 5 0.46). None of the deaths was attributed to the study drug upon review by the site investigator, the local Research Ethics Board and the DSMC.
All AEs and SAEs assessed by the site investigator to be reasonably related to the study drug are reported in Table 5 . There was no significant difference in the AE ratio (12.0%; 95% CI, 22.6 to 26.7; P 5 0.15) and the SAE ratio (23.2%; 95% CI, 213.7 to 7.8; P 5 0.55) between the vasopressin and placebo groups.
DISCUSSION
Despite earlier reports of improved urine output and favorable effects on short-term hemodynamic parameters, we found no evidence of improvement in clinical outcomes with low-dose † Vasoactive score: dose of dopamine 1 dobutamine 1 (epinephrine 3 100) 1 (norepinephrine 3 100) 1 (phenylephrine 3 100) 1 (milrinone 10).
vasopressin in this multicenter, randomized, placebo-controlled trial in children with vasodilatory shock. There are several possible reasons why the addition of vasopressin did not result in any demonstrable clinical benefit in the context of this trial. First, the dosage of vasopressin may have been insufficient. The dosage of vasopressin reported in the pediatric literature ranges from 0.00001 up to 0.008 U/kg/min and is primarily extrapolated from adult data. The dosage of vasopressin we used in this trial considered the current pediatric and adult experience (9) . A parallel decrease in vasopressin receptor responsiveness and a 1 -adrenergic receptors has been observed in experimental models of septic shock. Therefore, it has been suggested that patients with more severe vasodilatory shock may benefit from larger doses of vasopressin (28, 29) . However, given the evidence of * Values are presented as median and interquartile range unless otherwise noted. † Analyzed using cause-specific cumulative incidence approach. ‡ The number of days alive and free from vasoactive support in the 30-day period after randomization.
x The number of days alive and free or organ dysfunction as calculated by the MODS score in the 30-day period after randomization. { The number of days alive and free from ventilator support in the 30-day period after randomization. k The delta PELOD is the difference between the daily PELOD score at randomization and the worst daily PELOD score observed thereafter. Patients whose PELOD did not change or decreased after entry into the trial were considered to have a delta PELOD of zero. ** Vasoactive score: dose of dopamine 1 dobutamine 1 (epinephrine 3 100) 1 (norepinephrine 3 100) 1 (phenylephrine 3 100) 1 (milrinone 3 10).
adverse events with larger doses in adults (29, 30) , we cannot assume that higher doses of vasopressin would be beneficial or safe in children. Second, the timing of which vasopressin was administered may not have been optimal. However, the stage of shock during which the exogenous vasopressin may be most beneficial is unclear. Observational studies report a high mortality rate of 48% when vasopressin is used as a rescue therapy in children with refractory shock, leading to the hypothesis that earlier administration may be more beneficial (17) . Data from the adult Vasopressin in Septic Shock Trial suggest a survival benefit with earlier administration of vasopressin when the patient is in less severe shock (31) . However, this pediatric trial did not demonstrate any incremental benefit when vasopressin was administered early (i.e., before the development of a refractory shock state in children). A recent randomized, open-label trial of terlipressin as a rescue therapy for children in catecholamineresistant septic shock demonstrated increases in MAP and oxygenation with terlipressin but no statistical difference in the mortality (67.3 vs. 71.4%) (32) . However, the mortality rate in Yildizdas' trial was double that observed in our intervention group.
A third possible explanation for lack of demonstrable efficacy is that children enrolled in the study may have progressed from warm to cold shock. A proportion of children with septic shock are known to evolve from a high cardiac output and low systemic vascular resistance state to a low cardiac output, high systemic vascular resistance profile (18) . In this instance, vasopressin is unlikely to be of benefit and may be harmful because it increases left ventricular afterload (33) . Unfortunately, in the absence of real-time invasive hemodynamic or echocardiographic measurements, as was the case in the majority of our patients, the progression in hemodynamic status in children is difficult to assess clinically (34) .
The mortality was twice as high in the vasopressin group compared with the placebo group. This difference may be due to chance. Nonseptic causes of vasodilatory shock tended to occur more often in the vasopressin group, which may have contributed to the mortality difference. In the post hoc analysis of the VASST trial, a beneficial interaction between low-dose vasopressin and steroids was observed; however, we did not demonstrate a survival advantage in the subgroup of children who received low-dose vasopressin and steroids. One patient who died of cerebral edema also had liver dysfunction with normal ammonia. The role of vasopressin in patients with liver failure remains unclear. It has been postulated that the effect of vasopressin on central V 2 receptors may increase cerebral blood flow and thus exacerbate preexisting intracranial hypertension in the setting of severe hepatic encephalopathy with high ammonia (35) . Another patient in the vasopressin group died from progressive mesenteric ischemia after initial presentation with postradiation enterocolitis and sepsis. The splanchnic vascular effects of vasopressin are still a matter of debate. Several experimental studies have demonstrated compromised gut mucosal perfusion particularly after high-dose infusion of vasopressin analogs, whereas other studies suggest favorable systemic and splanchnic microcirculatory flow with low-dose therapy compared with norepinephrine, provided that sufficient fluid resuscitation is performed (36, 37) . Nevertheless, dose-dependent impaired tissue perfusion from potent vasoconstriction and resultant adverse sequelae, such as coronary ischemia, ischemic skin lesions, reduction in cardiac output and systemic oxygen delivery, new-onset tachyarrhythmias, and splanchnic hypoperfusion, are potential concerns with vasopressin therapy, especially among patients with shock and concurrent catecholamine pressor use (38) (39) (40) . Other reported potential side effects such as platelet aggregation and thrombogenic effects, hyponatremia, and worsening of liver function tests were not observed with the addition of low-dose vasopressin in this trial, and there were no clear differences in the AE and SAE rate between groups. Measurements of vasopressin levels in our cohort were consistent with a hormone deficient state; however, recent literature suggests limitations to the measurement of the mature hormone (41) . Interpretation of static measurements of vasopressin should therefore be interpreted with caution. Nevertheless, the increase in measured plasma vasopressin levels to the range of approximately 60 to 130 pg/ml resulting from exogenous vasopressin infusion was not accompanied by earlier shock reversal.
There are multiple challenges to conducting clinical trials in critically ill pediatric patients, such as feasibility due to the nature of the patient population, relatively small numbers of any single type of patient, and limited funding opportunities (42) . As a result, many therapeutic interventions, including the management of shock, have been adapted from adult literature without critical evaluation in children (43) . On this background, this trial has numerous strengths. This is the first randomized controlled trial to our knowledge to evaluate the use of arginine vasopressin in children with shock and represents a multicentered, collaborative effort of pediatric critical care practitioners. We chose to evaluate vasopressin as an adjunctive, catecholamine-sparing agent rather than as a rescue therapy in a clinical scenario already deemed refractory because of the weak evidence that exists with respect to the management of children with fluid refractory shock (5, 44) . As a result, we deliberately established pragmatic inclusion criteria and management guidelines to select patients for whom clinicians would potentially consider a second-line vasopressor agent and to strengthen the generalizability of the trial findings. Although the volume resuscitation administered in the two groups just before study drug infusion appears conservative, the median volume resuscitation administered on the day of enrolment of 123.9 ml/kg and 98.5 ml/kg, respectively, in the vasopressin and placebo groups was substantial and consistent with current pediatric recommendations for aggressive volume resuscitation before initiation and escalation in vasoactive therapy during shock (5) .
Potential weaknesses of this trial include the choice of time to hemodynamic stability as a primary outcome. Ideal endpoints for clinical trials in critically ill children have not been determined; therefore, investigators must often rely on surrogate endpoints to evaluate an intervention (45, 46) . Although it is unclear how well the time to vasoactive-free hemodynamic stability predicts survival, it is a clinically important outcome in that it reflects the resolution of shock and has significant potential economic implications on length of ICU and hospital stay and nursing resources. It is unlikely that a pediatric trial of this nature powered to reduce the typically lower mortality rates seen in this population would be feasible, given how few potentially eligible patients are admitted to each PCCU and considering that the adult VASST trial took 5 years and 27 international sites to recruit 776 patients (31) .
Endocrine dysfunction in critical illness is an evolving complex and inadequately understood area of research. The notion of exogenous replacement of a presumed hormone-deficient state appears to be too simplistic. The role of hormonal therapy clearly requires ongoing prospective study. However, based on the results of this multicentered trial and a potentially clinically important increase in mortality, we do not recommend the routine use of low-dose vasopressin infusion as an adjunctive agent for children in vasodilatory shock. These results can be used to better inform practice guidelines for hemodynamic support in children, which to date have been lacking in pediatric-specific, clinical trial evidence (47) .
